Agios Pharmaceuticals, Inc. (AGIO)
| Market Cap | 2.20B |
| Revenue (ttm) | 40.88M |
| Net Income (ttm) | 650.08M |
| Shares Out | 58.10M |
| EPS (ttm) | 11.13 |
| PE Ratio | 3.41 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 683,001 |
| Open | 37.19 |
| Previous Close | 36.42 |
| Day's Range | 36.68 - 38.02 |
| 52-Week Range | 23.42 - 62.58 |
| Beta | 0.87 |
| Analysts | Buy |
| Price Target | 57.00 (+50.2%) |
| Earnings Date | Oct 30, 2025 |
About AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patien... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for AGIO stock is "Buy." The 12-month stock price target is $57.0, which is an increase of 50.20% from the latest price.
News
AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES , Sept. 18, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agios Pharmaceutica...
AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $AGIO--AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm.
Agios Pharmaceuticals: Why A Delayed FDA Review Could Still Be A Positive
Agios faces a pivotal FDA decision on 7 December for mitapivat's thalassemia expansion, with a good chance of approval based on strong Phase 3 data. The stock has lagged typical pre-PDUFA momentum, of...
Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated
Agios Pharmaceuticals, Inc. faces a three-month FDA review delay for mitapivat in thalassemia due to safety concerns, but no new efficacy or safety data was requested. Despite the setback, I remain co...
FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use
On Thursday, the U.S. Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) goal date for Agios Pharmaceuticals, Inc.'s AGIO supplemental New Drug Application (sNDA) o...
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia
PDUFA goal date extended by three months from September 7, 2025, to December 7, 2025 CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage...
Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia
Agios Pharmaceuticals today announced that the Saudi Food and Drug Authority has approved PYRUKYND® for the treatment of adult patients with thalassemia
Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2025 Earnings Call July 31, 2025 8:00 AM ET Company Participants Brian M. Goff - CEO & Director Cecilia Jones - Chief Financial Officer Sarah Gheuens - Ch...
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update
$12.5 million in second quarter PYRUKYND® (mitapivat) net revenues; ended second quarter with $1.3 billion dollars in cash, cash equivalents and marketable securities PYRUKYND sNDA for thalassemia und...
Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET
CAMBRIDGE, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseas...
Agios Appoints Dr. Jay Backstrom to Board of Directors
CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseas...
Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders
AMSTERDAM--(BUSINESS WIRE)-- #biotech--Avanzanite Bioscience B.V. (“Avanzanite”), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patie...
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025
Agios Pharmaceuticals, Inc. announced that its management team is scheduled to present at the Goldman Sachs Healthcare Conference on June 9 at 8:40 a.m. ET
Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress
CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare disease...
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025
CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced...
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025
CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced...
Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Chris Taylor – Vice President-Investor Relations and Corporate Communications Br...
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights
– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND ® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Dis...
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025
CAMBRIDGE, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare disea...
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer
CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare disea...
Agios to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announc...
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025
CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announce...
Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Brian Goff - CEO Sarah Gheuens - CMO & Head OF R&D Tsveta Milanova - CCO C...
Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
– Filed for Regulatory Approval of Mitapivat (PYRUKYND ®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European U...
Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint
– ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused –